Members of European Parliament ask the Commission: Make COVID-19 tools affordable and available
Currently, EU-funded research projects do not contain legal provisions or requirements to ensure that end products will be made accessible, affordable, and available for patients and health care systems. Without these safeguards, end products, as well as scientific knowledge and data on the disease, generated with EU funding and expertise, risks being privatised, the MEPs argue. This in turn could lead to high prices and supply issues resulting in the rationing of medical tools and the loss of lives.
“We cannot allow patients to be refused care because of financial constraints or shortages resulting from manufacturing or supply constraints. From this moment forward, we require new medical tools to be immediately available once authorised for use, at an affordable price and in high enough quantities to meet global demand.”
The group encourages the European Commission to move away from a “business as usual” approach, and to place strict conditions on COVID-19 funding agreements. The use of worldwide, non-exclusive licensing is an option, the group suggests, because it enables a number of manufacturers of effective medical tools to rapidly scale up production to meet demands in Europe and elsewhere, resulting in competition that could lead to more affordable end products.
Petra De Sutter, MEP (Greens-EFA), said that the urgent priority of public health over profit was very clear: “Research institutes and the pharmaceutical industry are very important partners in the fight against COVID-19, but we cannot allow pharmaceutical companies to prioritise profit maximalisation at the expense of public health. Once approved, diagnostic tools, treatments, and vaccines for COVID-19 should be immediately accessible for everyone. The European Commission should take action on non-exclusive licensing to make this happen.”
Médecins Sans Frontières/Doctors Without Borders (MSF) Access Campaign and Health Action International (HAI) coordinated the letter as facilitators of the European Parliament Working Group on Innovation, Access to Medicines and Poverty-related Diseases.
Europe is currently at the epicenter of COVID-19 pandemic—in recent years access to affordable medicines has increasingly become a matter of concern in the EU.